Drug poisoning;Intoxicación por drogas

Anales del Sistema Sanitario de Navarra

Volumn 26, Issue SUPPL. 1, 2003, Pages 99-128

  Gainza, I ^a   Nogue S ^b   Martinez Velasco C ^c   Hoffman, R S ^f   Burillo Putze, G ^d   Duenas A ^e   Gomez J ^f   Pinillos, Miguel Ángel ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Clinica San Miguel   (Spain)

^d HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^f Hospital de Navarra ^*

Author keywords

Cannabis sative; Cocaine; Methadone; Opiates; The desing drug

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; AMPHETAMINE; BENZODIAZEPINE DERIVATIVE; CANNABINOID; CANNABIS; COCAINE; DIAMORPHINE; FLUMAZENIL; ILLICIT DRUG; KETAMINE; LYSERGIDE; METHADONE; MIDAZOLAM; NALOXONE; OPIATE DERIVATIVE; PHENTOLAMINE; PHYSOSTIGMINE; PROPRANOLOL; PSYCHEDELIC AGENT; VERAPAMIL;

AGITATION; ALGORITHM; CLINICAL FEATURE; DRUG ABUSE; DRUG INTOXICATION; EMERGENCY HEALTH SERVICE; HUMAN; REVIEW;

EID: 0037933294     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. United Nations. Office of Drugs and Crime (UNODC) Web: www.unodc.org
2. Fundación de Ayuda contra la Drogadicción. Web: www.fad.org
3. Plan Nacional sobre drogas. Observatorio Español sobre drogas. Ministerio del Interior. Web: www.mir.es/pnd/Observa
4. a Ed. Pergamon Press, Nueva York, 1990.
5. SCHAUBEN JL. Opioids. En: IRWIN RS, CERRA FB, RIPPE JM, eds. Irwin and Rippe's Intensive Care Medicine. Baltimore, Md: Lippincott Williams & Wilkins; 1999: 1744-1754.
6. a ed. Little Brown. Boston, 1988.
7. ESCOHOTADO A. Historia General de las drogas, Tomo II. Alianza editorial, España, 1995.
8. DOLE VP NYWANDER ME. A medical treatment for dyacetilmorphine (heroine) addiction. A clinical trial with methadone hidrocloride. JAMA 1965; 193: 646-650.
9. ZWEBEN JE, PAYTE JT. Methadone maintenance in the treatment of opioid dependence: a current perspective. West J Med 1990; 152: 588-599.
10. BOERNER U. The metabolism of morphine an heroine in man. Drug Metab Rev 1975; 4: 39-73.
11. WANGER K, BROUGH L, MACMILLAN I, GOULDING J, MACPHAIL I, CHRISTENSON JM. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med 1998; 5: 293-299.
12. a ed. Philadelphia: Lippicott-Raven Publishers, 1996; 1382-1386.
13. JAFFE RB, KOSCHMAN EB. Intravenous drug abuse. Pulmonary, cardiac and vascular complications. Am J Roentgenol Radium Ther Nucl Med 1970; 109: 107-120.
14. SPORER A. Acute heroin overdose. Ann Intern Med 1999; 130: 584-590.
15. NELSON LS. Opioids. En: Goldfrank LR, Flomenbaum NR, eds. Goldfrank's Toxicologic Emergencies. New York, NY: McGraw-Hill; 1998: 975-999.
16. OSTERWALDER JJ. Naloxone for intoxications with intravenous heroin and heroin mixtures harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol 1996; 34: 409-416.
17. MONFORTE JR. Some observations concerning blood morphine concentrations in narcotic addicts. J Forensic Sci 1977; 22: 718-724.
18. CLARK JC, MILROY MC, FORREST AR. Deaths from methadone overdose. J Clin Forensic Med 1995; 2: 143-144.
19. AMATO L, DAVOLI M, FERRI M, ALI R. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2002: 2CD00340.
20. THOMPSON A. Toxic action of cocaine. Br Med J 1886.
21. GARLAND OH, BOIN FR. Fatal acute poisoning by cocaine. Lancet 1895; 2: 1104.
22. NAVARRO J. El consumo de dorgas. En: FAD y colaboradores. Sociedad y drogas: una perspectiva de 15 años. Madrid, Fundación de Ayuda contra la Drogadicción 2002: 98-116.
23. o 4, Marzo 2001. Madrid. Ministerio del Interior, Delegación del Gobierno para el Plan Nacional sobre Drogas. 2001.
24. HOFFMAN RS, HENRY GC, HOWLAND MA, WEISMAN RS, WEIL L, GOLDFRANK LR. Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann Emerg Med 1992; 21: 247-253.
25. SMITH JA, MO Q, GOU H, KUNKO PM, ROBINSON SE. Cocaine increases extraneuronal levels of aspartate and glutamate in the nucleus accumbens. Brain Res 1995; 683: 264-269.
26. TELLA SR, SCHINDLER CW, GOLDBERG SR. Cocaine: cardiovascular effects in relation to inhibition of peripheral neuronal monoamine uptake and central stimulation of the sympathoadrenal system. J Pharmacol Exp Ther 1993; 267: 153-162.
27. GIROS B, JABER M, JONES SR, WIGHTMAN RM, CARON MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606-612.
28. HAHN I, HOFFMAN RS. Cocaine use and acute myocardial infarction. Emerg Med Clin North Am 2001; 19: 493-510.
29. GOLDFRANK LR, HOFFMAN RS. The cardiovascular effects of cocaine. Ann Emerg Med 1991; 20: 165-175.
30. MCCANCE EF, PRICE LH, KOSTEN TR, JATLOW PI. Cocaethylene: pharmacology, physiology and behavioral effects in humans. J Pharmacol Exp Ther 1995; 274: 215-223.
31. GRANDALL CG, VONGPATANASIN W, VICTOR RG. Mechanism of cocaine-induce hyperthermia in humans. Ann Intern Med 2002; 136: 785-791.
32. KLONER RA, REZKALLA SH. Cocaine and the heart. N Engl J Med 2003; 348: 487-488.
33. LANGE RA, HILLIS D. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345: 351-358.
34. TAZELAAR HD, KARCH SB, STEPHENS BG, BILLINGHAM ME. Cocaine and the heart. Hum Pathol 1987; 18: 195-199.
35. PANACEK EA, SINGER AJ, SHERMAN BW, PRESCOTT A, RUTHERFORD WF. Spontaneous pneumomediastinum: clinical and natural history. Ann Emerg Med 1992; 21: 1222-1229.
36. HAIM DY, LIPPMANN ML, GOLDBERG SK, WALKENSTEIN MD. The pulmonary complications of crack cocaine. A comprehensive review. Chest 1995; 107: 233-240.
37. QURESHI AI, SURI MF, GUTERMAN LR, HOPKINS LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation 2001; 103: 502-506.
38. HOLLANDER JE, HOFFMAN RS, GENNIS P, FAIRWEATHER P, DISANO MJ, SCHUMB DA et al. Nitroglycerin in the treatment of cocaine associated chest pain-clinical safety and efficacy. J Toxicol Clin Toxicol 1994; 32: 243-256.
39. LANGE RA, CIGARROA RG, FLORES ED, MCBRIDE W, KIM AS, WELLS PJ et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990; 112: 897-903.
40. WEBER JE, SHOFER FS, LARKIN GL, KALARIA AS, HOLLANDER JE. Validation of a brief observation period for patients with cocaine-associated chest pain. N Engl J Med 2003; 348: 507-510.
41. DERLET RW, ALBERTSON TE, THARRAT RS. Lidocaine potentiation of cocaine toxicity. Ann Emerg Med 1991; 20: 135-138.
42. NOGUE S, LUCA QUAGLIO G. El estómago y el intestino unos órganos con pluriempleo. Med Clin (Barc): 1998; 111: 338-340.
43. HUNG O, DUEÑAS A. Portadores humanos de drogas. En: Dueñas Laita A. ed. Intoxicaciones agudas en medicina de urgencia y cuidados críticos. Barcelona: Masson, S.A.; 1999: 353-356.
44. GÓMEZ M, CUENCA C, FARFÁN A, VILLALBA MV, TORO J, GARCÍA J. Complicaciones en transportadores intestinales de paquetes con cocaína. Estudio de 215 casos. Med Clin (Barc) 1998; 111: 336-337
45. PÉREZ C, HERNÁNDEZ F, ALONSO JL, ENAMORADO R, SANTOS J, MÁRQUES E. Síndrome mini-packer e intoxicación letal por cocaína: rabdomiolisis, fallo multiorgano e isquemia intestinal. Med Intensiva 1993; 17: 289-292.
46. HOLLINGSWORTH J, JONES R. Managing self poisoning. Body packers need careful treatment. Br Med J 2000; 320: 712.
47. DUEÑAS LAITA A, BURILLO PUTZE G. Nuevas tendencias en emergencias toxicológicas. En: Álvarez JA, Perales N (Eds). Avances en emergencias y resucitación (V). Madrid: Edikamed; 2002: 109-122.
48. CLARAMONTE X, NOGUÉ S, MONSALVE C. ¿Nuevas drogas de diseño? ¿Nuevas drogas de síntesis? F Med Cont 2002; 9: 323-334.
49. o 4 (marzo 2001). Ministerio del Interior. http://www.mir.es/pnd
50. RICAURTE GA, YUAN J, HATZIDIMITRIOU G, CORD BJ, MCCANN UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). Science 2002; 297: 2260-2263.
51. KISH SJ, FUROKAWA Y, ANG L, VORCE SP, KALASINSKY KS. Striatal serotonin is depleted in brain of a human MDMA (ecstasy) user. Neurology 2000; 55: 294-296.
52. RENEMAN L, LAVALAYE J, SCHMAND B, DE WOLFF FA, DEN BRINK WV, DEN HEETEN GJ, et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"). Arch Gen Psychiatry 2001; 58: 901-906.
53. TREJO O, ORTEGA M, PEREA M, NOGUÉ S. Fallo multiorgánico asociado al consumo de éxtasis. Rev Clin Esp 2001; 201: 108-109.
54. BALANZÓ X, RAFEL J, DE LA TORRE R, CAMÍ J.Intoxicación aguda mortal pormetilendioxianfetamina. Med Clin (Barc) 1996; 106: 718.
55. ANDREU V, MAS A, BRUGUERA M, SALMERÓN JM, MORENO V, NOGUÉ S et al. Ecstasy: A common cause of severe acute hepatoloxicity J Hepatology 1998; 29: 394-397.
56. NUÑEZ O, BAÑARES R, BARRIO J, MENCHEN L, DIEGO A, SALINERO E et al. Variabilidad de la expresión clínica de la hepatotoxicidad por éxtasis. Gastroenterol Hepatol 2002; 25: 497-500.
57. ZVOSEC DL, SMIT SH, MCCUTCHEON R, SPILLANE J, HALL BJ, PEACOCK EA. Adverse events, including death, associated with the use of 1,4-butanediol. N Eng J.Med 2001; 344: 87-94.
58. DUEÑAS A. Ácido gamma-hidroxibutírico o "éxtasis líquido" ¿La intoxicación que viene? Med Clin (Barc) 1998; 111: 458-460.
59. ESPINOSA G, MIRÓ O, NOGUÉ S, TO-FIGUERAS J, SANCHEZ M, COLL-VINENT B. Intoxicación por éxtasis líquido: estudio de 22 casos. Med Clin (Barc) 2001; 117: 56-58.
60. SCHWARTZ RH, MILTEER R, LEBEAU M. Drug-facilitated sexual assault ("date rape"). South Med J 2000; 93: 558-561.
61. MIRÓ O, NOGUÉ S, ESPINOSA G, TO J, SÁNCHEZ M. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutirate. Clin Toxicol 2002; 40: 129-135.
62. TIMBY N, ERIKSSON A, BOSTRÖM K. Gamma-hydroxybutyrate-associated deaths. Am J Med 2000; 108: 518-519.
63. CALDICOTT GE, KUHN M. Gamma-hydroxybuty-rate overdose and physostigmine; teaching new tricks to an old drug? Ann Emerg Med 2001; 37: 99-102.
64. GRAEME KA. New drugs of abuse. Emerg Med Clin North America 2000; 18: 625-636.
65. GAULIER JM, CANAL M, PRADEILLE JL, MARQUET P, LACHATRE G. Nouvelles drogues dans les "rave parties": ketamine et prolintane. Acta Clin Belg Suppl 2002; 1: 41-46.
66. GILL JR, STAJIC M. Ketamine in non-hospital and hospital deaths in New York city. J Forensic Sci 2000; 45: 655-658.
67. TOUW M. The religious and medicinal uses of cannabis in China, India and Tibet. J Psychoactive Drugs 1981; 13: 23-34.
68. BRUNNER T F. Marijuana in ancient Greece and Rome. The literary evidence. Bull Hist Med 1973; 47: 344-348.
69. MOREAU JJ. Hashish and mental illness. Raven Press. New York. Traducción del original publicado en francés en 1845; 1973.
70. WALLER CW. Chemistry of marihuana. Pharmacol. Rev. 1971; 23: 265-271.
71. JÄRBE TUC, MATHIS DA. Dissociative and discriminative stimulus functions of cannabinoids/cannabimimetics. Biochemi and Physiol Substance Abuse, 1992; 4: 459-524, Boca Ratón, CRC Press
72. MUNRO S, THOMAS KL, ABUA SHAAR M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
73. WIDMAN M, AGURELL S, EHRNEBO M, JONES G. Binding of (+) and (-) Δ1-THC and (-) -7-hidroxy-d1THC to blood cells and plasma proteins in man. J Pharm Pharmacol 1974; 26: 914-916.
74. DEVANE WA, DISARZ FA 3rd, JOHNSON MR, HELVIN SL, HOWLETT AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-613.
75. DEVANE WA, HANUS L, BRENER A, PERTWEEF RG, STEVENSON LA, GRIFFIN G et al. Isolation and estructure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
76. PERTWEE RG. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neural non-CB1 cannabinoid receptors. Life Sci 1999; 65: 597-605.
77. MANZANARES J CORCHERO J, ROMERO J FERNÁNDEZ RUIZ JS, RAMOS JA, FUENTE JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20: 287-294.
78. DOBIN RE, KLEIMAN M. Marijuana as antiemetic medicine: a survey of oncologist experience and attitudes. J Clin Oncology 1991: 1314-1319.
79. CONSROE P. Potential role of cannabinoids for therapy of neurological disorders. En: Marijuana/Cannabinoids. Neurobiology and Neurophysiology (Eds. Murpy, Bartke), Sandyk 1992; 459-524, Boca Raton: CRC Press.
80. SKAPER SD, BURIANI A, DAL-TOSO R, PETRILLI L, ROMANELLO S, FACCI L et al. The aliamide palmitoglethandemide and cannabinoids, dot not anandamide, are protective in a delayed postglutamate paradigms of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 1996; 93: 3984-3989.
81. MATHEW RJ, WILSON WH, HUMPHREYS D, LOWE JV, WEITHE KE Depersonalization after marijuana smoking. Biol Psychiatry 1993; 33: 431-441.
82. WALSH GW, MANN RE. On the high road: driving under the influence of cannabis in Ontario. Can J Public Health 1999; 90: 260-263.
83. SOLOWIJ N, STEPENS RS, ROTTMAN RA, BABOR T, KALDDEN R, MILLER M et al. Cognitive functinoning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123-1131.
84. DISDIER P, SWIADER, JOUGLARD J, PIQUET P, CHRISTISES C, MOULIN G et al. Cannabis induced arteritis vs. leo Buerger disease. Nosologic discussion a propos of two new cases. Presse Med. 1999; 16 28: 71-74.
85. MASSET D, BOURDON JH, ARDITTI DJIASE J, JOUGLARD J. Impact of Δ9-THC and its metabolitos on the inmune system. Acta Clin Belg Suppl 1999; 1: 39-43.
86. HANEY M, WARD AS, COMER 50, FOLTIN RW, FISCHMAN MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl.) 1999; 141: 395-402.
87. HANEY M, WARD AS, COMER 50, FOLTIN RW, FISCHMAN MW. Abstinence symptoms following oral THC administration in humans. Psychopharmacology (Berl.) 1999 141:385-394.
88. UNGERLEIDER JT, Pechnick RN. Alucinógenos. En: Galanter M., Cléber H. (Eds.) Tratamiento de los trastornos por abuso de sustancias de la American Psychiatric Press. Masson, 1997; 141-147.
89. a edición. Masson 1996; 319-334.
90. GARCÍA ROLLÁN, M. 1999. El caso especial de los hongos alucinógenos dentro del artículo "Conservación de la biodiversidad de hongos superiores y control de la recogida de setas y trufas". Sociedad Micológica de Madrid, Real Jardín Botánico. Madrid.
91. GÓMEZ URRUTIA, J.. Colección Carteles: Setas de nuestro entorno. Confusiones y diferencias. S.C.N. Gorosti en colaboración con el Servicio Navarro de Salud. Pamplona, 2001.
92. GARCÍA BONA L.M. Catalogo micólogico de Navarra 2000. Monografía de la S.C.N. Gorosti. Pamplona. 2000.